-
Glucotrack receives three USPTO patents for glucose monitoring system
-
GlucoTrack (GCTK) files for 3.22M share offering by selling stockholders
-
GlucoTrack (GCTK) files for 20.06M share offering by selling stockholders
-
Glucotrack appoints cardiologist David Hirsh as medical director
-
Glucotrack repurchases over 90% of Series A warrants
-
GlucoTrack (GCTK) and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
-
GlucoTrack (GCTK) Announces 1:60 Reverse Share Split
-
GlucoTrack (GCTK) elects Victoria Carr-Brendel to Board
-
GlucoTrack (GCTK) and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
-
GlucoTrack (GCTK) Appoints Guillermo Umpierrez to Medical Advisory Board
-
GlucoTrack (GCTK) Prices 2.6M Share Offering at $1.15/sh
-
GlucoTrack (GCTK) Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
-
GlucoTrack (GCTK) Announces 1:20 Reverse Share Split
-
GlucoTrack (GCTK) Strengthens Leadership Team with Appointment of New Chief Financial Officer
-
GlucoTrack (GCTK) Announces ISO 13485:2016 Certification
-
GlucoTrack (GCTK) Appoints Ted Williams as Vice President of Regulatory Affairs
-
Glucotrack (GCTK) Prices $10M Share Offering
-
GlucoTrack (GCTK) Files $30M Mixed Shelf
-
GlucoTrack (GCTK) Appoints John Ballantyne to its Board
-
GlucoTrack (GCTK) Announces New Vice President Of Clinical Operations
-
GlucoTrack (GCTK) Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey
-
GlucoTrack (GCTK) Appoints Andy Balo to its Board

